MXPA03010919A - Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor. - Google Patents

Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.

Info

Publication number
MXPA03010919A
MXPA03010919A MXPA03010919A MXPA03010919A MXPA03010919A MX PA03010919 A MXPA03010919 A MX PA03010919A MX PA03010919 A MXPA03010919 A MX PA03010919A MX PA03010919 A MXPA03010919 A MX PA03010919A MX PA03010919 A MXPA03010919 A MX PA03010919A
Authority
MX
Mexico
Prior art keywords
carnitine
medication
acetyl
pain
preparation
Prior art date
Application number
MXPA03010919A
Other languages
English (en)
Spanish (es)
Inventor
Calvani Menotti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MXPA03010919A publication Critical patent/MXPA03010919A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MXPA03010919A 2001-05-29 2002-05-24 Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor. MXPA03010919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000293A ITRM20010293A1 (it) 2001-05-29 2001-05-29 Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
PCT/IT2002/000336 WO2002096409A1 (en) 2001-05-29 2002-05-24 Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain

Publications (1)

Publication Number Publication Date
MXPA03010919A true MXPA03010919A (es) 2004-02-27

Family

ID=11455557

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010919A MXPA03010919A (es) 2001-05-29 2002-05-24 Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.

Country Status (18)

Country Link
US (2) US20040152781A1 (enExample)
EP (1) EP1399141B1 (enExample)
JP (1) JP4287660B2 (enExample)
KR (1) KR100873748B1 (enExample)
AT (1) ATE374021T1 (enExample)
CA (1) CA2448242C (enExample)
CY (1) CY1107037T1 (enExample)
CZ (1) CZ20033220A3 (enExample)
DE (1) DE60222662T2 (enExample)
DK (1) DK1399141T3 (enExample)
ES (1) ES2290292T3 (enExample)
HU (1) HUP0401294A3 (enExample)
IT (1) ITRM20010293A1 (enExample)
MX (1) MXPA03010919A (enExample)
PL (1) PL367616A1 (enExample)
PT (1) PT1399141E (enExample)
SK (1) SK287559B6 (enExample)
WO (1) WO2002096409A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040606A1 (it) * 2004-12-13 2005-03-13 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica.
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニSigma−Tau Industrie Farmaceutiche Riunite Societa Per Azioni 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン
IT202200022437A1 (it) 2022-11-02 2024-05-02 Chiesi Italia S P A Composizione farmaceutica comprendente l-acetilcarnitina e beta-cariofillene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150688B1 (en) * 1983-12-28 1987-04-22 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Also Published As

Publication number Publication date
DK1399141T3 (da) 2008-01-02
SK15842003A3 (sk) 2004-06-08
DE60222662T2 (de) 2008-06-26
CY1107037T1 (el) 2012-09-26
PT1399141E (pt) 2007-11-16
HUP0401294A2 (hu) 2004-12-28
ITRM20010293A1 (it) 2002-11-29
EP1399141A1 (en) 2004-03-24
WO2002096409A1 (en) 2002-12-05
JP4287660B2 (ja) 2009-07-01
CA2448242C (en) 2011-01-11
PL367616A1 (en) 2005-03-07
DE60222662D1 (de) 2007-11-08
JP2004532865A (ja) 2004-10-28
ES2290292T3 (es) 2008-02-16
SK287559B6 (sk) 2011-02-04
KR100873748B1 (ko) 2008-12-12
ITRM20010293A0 (it) 2001-05-29
CA2448242A1 (en) 2002-12-05
HUP0401294A3 (en) 2008-04-28
CZ20033220A3 (en) 2004-06-16
ATE374021T1 (de) 2007-10-15
US20040152781A1 (en) 2004-08-05
KR20040003030A (ko) 2004-01-07
US20090062388A1 (en) 2009-03-05
EP1399141B1 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
MXPA03007712A (es) Sales farmaceuticas.
MY125821A (en) Pharmaceutical composition of topiramate
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
IL196301A0 (en) Medicament for the treatment of hapatitis c
PT1441705E (pt) Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
PL372457A1 (en) New pharmaceutical compositions containing flibanserin polymorph a
EP1440690A3 (en) Treatment of neurotic disorders
PL367616A1 (en) Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
AP2001002369A0 (en) Pharmaceutical complex.
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
IL160486A0 (en) Citalopram for the treatment of elevated blood pressure
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
PL367634A1 (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
WO2005060978A3 (en) Polymetaphosphate based formulations for therapy of microcrystalline arthropathies
AU2002258182A1 (en) Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
SI1817029T1 (sl) Derivati izoksazola za lajĺ anje nevropatskih boleäśin
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.

Legal Events

Date Code Title Description
FG Grant or registration